Catalyst Pharmaceuticals Inc’s recent filing unveils that its Chief Compliance/Legal Officer Elsbernd Brian unloaded Company’s shares for reported $0.41 million on Mar 27 ’24. In the deal valued at $16.44 per share,25,000 shares were sold. As a result of this transaction, Elsbernd Brian now holds 124,433 shares worth roughly $1.93 million.
Then, Harper Molly sold 14,000 shares, generating $201,420 in total proceeds. Upon selling the shares at $14.39, the Director now owns 0 shares.
Before that, Tierney David S sold 50,000 shares. Catalyst Pharmaceuticals Inc shares valued at $666,250 were divested by the Director at a price of $13.32 per share. As a result of the transaction, Tierney David S now holds 333,541 shares, worth roughly $5.17 million.
Citigroup initiated its Catalyst Pharmaceuticals Inc [CPRX] rating to a Buy in a research note published on March 14, 2024; the price target was $27. A number of analysts have revised their coverage, including BofA Securities’s analysts, who began to cover the stock in early March with a ‘”a Buy”‘ rating. Oppenheimer began covering CPRX with “an Outperform” recommendation on December 21, 2023. ROTH Capital revised its rating on August 24, 2022. It rated CPRX as “a Neutral” which previously was an “a Buy”.
Price Performance Review of CPRX
On Monday, Catalyst Pharmaceuticals Inc [NASDAQ:CPRX] saw its stock jump 2.24% to $15.51. Over the last five days, the stock has lost -1.46%. Catalyst Pharmaceuticals Inc shares have fallen nearly -7.73% since the year began. Nevertheless, the stocks have fallen -8.39% over the past one year. While a 52-week high of $18.22 was reached on 03/01/24, a 52-week low of $11.09 was recorded on 02/08/24. SMA at 50 days reached $15.08, while 200 days put it at $14.04. A total of 0.93 million shares were traded, compared to the trading of 0.99 million shares in the previous session.
Levels Of Support And Resistance For CPRX Stock
The 24-hour chart illustrates a support level at 15.15, which if violated will result in even more drops to 14.79. On the upside, there is a resistance level at 15.89. A further resistance level may holdings at 16.26. The Relative Strength Index (RSI) on the 14-day chart is 48.66, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.57, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 78.05%. Stochastics %K at 11.01% indicates the stock is a buying.
How much short interest is there in Catalyst Pharmaceuticals Inc?
A steep rise in short interest was recorded in Catalyst Pharmaceuticals Inc stocks on Mar 15, 2024, growing by 0.16 million shares to a total of 5.83 million shares. Yahoo Finance data shows the prior-month short interest on Feb 15, 2024 was 5.67 million shares. There was a rise of 2.74%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 6.10% of the overall stock float, the days-to-cover ratio (short ratio) rose to 3.79.
The most recent change occurred on September 21, 2018 when Cantor Fitzgerald began covering the stock and recommended ‘”an Overweight”‘ rating .
